- Home
- QH vs CRDL Comparison
QH vs CRDL Comparison
Compare QH & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- CRDL
- Stock Information
- Founded
- QH 2012
- CRDL 2017
- Country
- QH China
- CRDL Canada
- Employees
- QH N/A
- CRDL N/A
- Industry
- QH Business Services
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QH Consumer Discretionary
- CRDL Health Care
- Exchange
- QH Nasdaq
- CRDL Nasdaq
- Market Cap
- QH 104.9M
- CRDL 112.4M
- IPO Year
- QH 2020
- CRDL N/A
- Fundamental
- Price
- QH $1.30
- CRDL $1.30
- Analyst Decision
- QH
- CRDL Strong Buy
- Analyst Count
- QH 0
- CRDL 2
- Target Price
- QH N/A
- CRDL $9.00
- AVG Volume (30 Days)
- QH 22.2K
- CRDL 210.2K
- Earning Date
- QH 08-27-2025
- CRDL 08-11-2025
- Dividend Yield
- QH N/A
- CRDL N/A
- EPS Growth
- QH N/A
- CRDL N/A
- EPS
- QH 0.01
- CRDL N/A
- Revenue
- QH $417,431,053.00
- CRDL N/A
- Revenue This Year
- QH N/A
- CRDL N/A
- Revenue Next Year
- QH N/A
- CRDL N/A
- P/E Ratio
- QH $144.82
- CRDL N/A
- Revenue Growth
- QH N/A
- CRDL N/A
- 52 Week Low
- QH $0.25
- CRDL $0.77
- 52 Week High
- QH $2.27
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- QH 54.65
- CRDL 47.68
- Support Level
- QH $1.16
- CRDL $1.22
- Resistance Level
- QH $1.45
- CRDL $1.54
- Average True Range (ATR)
- QH 0.09
- CRDL 0.10
- MACD
- QH 0.01
- CRDL -0.01
- Stochastic Oscillator
- QH 42.23
- CRDL 28.33
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.